2-bromo-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide | 675834-23-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide
• 英文别名: 2-bromo-N-[2-fluoro-4-(2-methylsulfonylphenyl)phenyl]acetamide
• CAS: 675834-23-8
• 化学式: C₁₅H₁₃BrFNO₃S
• 分子量: 386.242
• InChiKey: BAPLQWLOUYSCLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  593.8±50.0 °C(Predicted)
• 密度：
  1.563±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2-[3-(4-Chloro-phenyl)-1-ethyl-ureido]-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide
  参考文献：
  名称：

  The discovery of glycine and related amino acid-based factor Xa inhibitors

  摘要：

  Herein, we report on the identification of three potent glycine and related amino acid-based series of FXa inhibitors containing a neutral P1 chlorophenyl pharmacophore. A X-ray crystal structure has shown that constrained glycine derivatives with optimized N-substitution can greatly increase hydrophobic interactions in the FXa active site. Also, the substitution of a pyridone ring for a phenylsulfone ring in the P4 sidechain resulted in an inhibitor with enhanced oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.02.040
• 作为产物：
  描述：

  溴乙酰氯 、 2-fluoro-4-(2-methylsulfonylphenyl)aniline 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以92%的产率得到2-bromo-N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acetamide
  参考文献：
  名称：

  [EN] INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
  [FR] INHIBITEURS DE FACTEUR XA ET AUTRES SERINE PROTEASES INTERVENANT DANS LA CASCADE DE COAGULATION

  摘要：

  该发明揭示了显示对丝氨酸蛋白酶Xa具有抑制作用的氨基酸衍生物。该发明还揭示了该化合物的药用盐、包含该化合物或其盐的药用组合物、制备该化合物的方法，以及将其用作治疗或预防哺乳动物异常血栓形成疾病状态的治疗剂的方法。

  公开号：

  WO2004024679A1

文献信息

• Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
  申请人：Pfizer Inc.

  公开号：US20040167131A1

  公开（公告）日：2004-08-26

  This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

  本发明揭示了一种氨基酸衍生物，其显示出对丝氨酸蛋白酶Xa的抑制效果。该发明还揭示了该化合物的药学上可接受的盐、包含该化合物或其盐的药学上可接受的组合物，制备该化合物的方法以及将其用作治疗或预防哺乳动物异常血栓病状态的治疗剂的方法。
• [EN] INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE<br/>[FR] INHIBITEURS DE FACTEUR XA ET AUTRES SERINE PROTEASES INTERVENANT DANS LA CASCADE DE COAGULATION
  申请人：WARNER LAMBERT CO

  公开号：WO2004024679A1

  公开（公告）日：2004-03-25

  This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

  该发明揭示了显示对丝氨酸蛋白酶Xa具有抑制作用的氨基酸衍生物。该发明还揭示了该化合物的药用盐、包含该化合物或其盐的药用组合物、制备该化合物的方法，以及将其用作治疗或预防哺乳动物异常血栓形成疾病状态的治疗剂的方法。
• The discovery of glycine and related amino acid-based factor Xa inhibitors
  作者：Jeffrey T. Kohrt、Kevin J. Filipski、Wayne L. Cody、Christopher F. Bigge、Frances La、Kathleen Welch、Tawny Dahring、John W. Bryant、Daniele Leonard、Gary Bolton、Lakshmi Narasimhan、Erli Zhang、J. Thomas Peterson、Staci Haarer、Vaishali Sahasrabudhe、Nancy Janiczek、Shrilakshmi Desiraju、Mostofa Hena、Charles Fiakpui、Neerja Saraswat、Raman Sharma、Shaoyi Sun、Samarendra N. Maiti、Robert Leadley、Jeremy J. Edmunds

  DOI：10.1016/j.bmc.2006.02.040

  日期：2006.7

  Herein, we report on the identification of three potent glycine and related amino acid-based series of FXa inhibitors containing a neutral P1 chlorophenyl pharmacophore. A X-ray crystal structure has shown that constrained glycine derivatives with optimized N-substitution can greatly increase hydrophobic interactions in the FXa active site. Also, the substitution of a pyridone ring for a phenylsulfone ring in the P4 sidechain resulted in an inhibitor with enhanced oral bioavailability. (c) 2006 Elsevier Ltd. All rights reserved.